HCW Biologics (HCWB) said Tuesday that studies show its HCW9206 fusion protein opens up a new pathway for generating chimeric T-cell receptors for immunotherapy with increased function.
The clinical-stage company said HCW9206 has the potential to "significantly" reduce costs while improving clinical efficacy of engineered effector T-cells.
The data were presented at the annual meeting of American Association of Immunologists in Honolulu, Hawaii, the company said.
HCW said it is now seeking commercial partnerships for HCW9206 reagent sale and/or integration into CAR-T based manufacturing processes.
Shares of the company were up 153% in recent trading on Tuesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。